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For the 27th time in a row the Netherlands Heart Insti-
tute (NHI, formerly ICIN) and the Netherlands Society
of Cardiology (NVVC) supported the competition for the
three best cardiovascular PhD theses, published in the year
2015 [1–5]. The dissertation prize carries the name of one
of the greatest Dutchmen in the history of cardiovascular
medicine, Willem Einthoven, who in 1902 for the first time
recorded the human ECG, for which he received the Nobel
Prize in 1924 [6].
This time the jury received a total of 19 PhD disserta-
tions published in 2015. The jury members were very much
impressed by the high scientific quality of the PhD fellows.
The ultimate selection was based on a combination of sev-
eral parameters: the curriculum vitae of the candidate, the
scientific originality of the PhD thesis and its relevance for
the cardiovascular field. In addition, several objective bib-
liometric parameters were used: 1) the number of articles in
first-rate journals both in PubMed and the Web of Science
(WOS), 2) the number of citations in WOS, 3) the Hirsch
Index, and 4) the contribution as a first author (or shared
first author).
Based on a combination of these results, the jury finally
selected three nominees: W.L. Verloop (University Medi-
cal Center Utrecht), T.P. van de Hoef (Academic Medical
Center, Amsterdam), and P.F.A. Teunissen (VUMC, Ams-
terdam).
The members of the jury were: P.A. Doevendans (Direc-
tor NHI), D.J. Duncker (Director NHI), J.W. Deckers (Di-
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rector CVOI), A. Mosterd (Chairman WCN), M.J. Schalij
(Chairman Concilium NVVC), and B.J. Mulder (President
NVVC).
The three candidates presented their PhD theses at
the annual Spring Congress of the NVVC, held at the
Congress Centre “De Leeuwenhorst” in Noordwijkerhout,
on 31 March and 1 April 2016. We thank the laureates for
their excellent presentations and we wish them a prosperous
scientific career.
Summary
The dreams of renal denervation: a translational
approach
In 2009, renal denervation (RDN) was presented for pa-
tients with resistant hypertension. The rationale behind
RDN is that chronic (hyper)activation of the sympathetic
nervous system is the cause of hypertension. However, the
exact mechanism behind RDN is unknown. Moreover, it
is of interest which patient categories would benefit from
RDN, especially since RDN is irreversible, and whether
RDN can also be used in other diseases characterised by
a (hyper)active sympathetic tone.
In an analysis of all patients referred for RDN, we
showed that two-thirds were excluded from treatment: 25 %
of these patients appeared to have “white-coat” resistant
hypertension and 12 % had a secondary cause of hyperten-
sion. This was remarkable since all referred patients had an
extensive history of hypertension. We therefore proposed
a screening protocol that has been adapted by most Dutch
hospitals performing RDN.
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To further identify eligible patients, we performed a ret-
rospective analysis to predict successful therapy. We
showed a relation between renal function (by means of
estimated glomerular filtration rate) and a blood pressure
(BP) reduction. To our knowledge, we were the first to ob-
serve that patients with chronic kidney disease may benefit
from RDN.
We also analysed the effects after RDN in our popula-
tion. Unlike other centres, we standardised the antihyper-
tensive drug conditions to prevent potential disturbances.
We observed a less prominent reduction in BP. Moreover,
in a substudy we observed no effect on sympathetic activity
despite a BP reduction in most patients. In conclusion, we
did not observe significant changes in end-organ damage,
such as left ventricular mass.
Besides hypertension, the metabolic syndrome is also
characterised by an overactive sympathetic nervous system.
Therefore we investigated the effect of RDN on insulin sen-
sitivity, BP, and sympathetic activity in a metabolic popula-
tion. We showed that RDN did not lead to an improvement
of insulin sensitivity at 12-month follow-up, nor did we ob-
serve a reduction in sympathetic activity. In this population,
we did observe a moderate reduction in ambulatory 24-hour
BP. However, this may be explained by the phenomenon of
“regression to the mean”, since frequent home-based BP
measurements did not change during the 12 months after
RDN.
To gain more insight into the RDN mechanism, we de-
signed a porcine model to study the effect on renal vas-
culature and haemodynamic changes in the kidneys them-
selves. There was a reduction in microvascular resistance.
However, the most prominent observations were a limited
penetration up to 2 mm deep in the artery wall and that
most of the renal nerves were remote to the vascular lumen
and therefore not reached by the delivered radiofrequency
energy. Furthermore, we observed a relation between more
vascular damage and pronounced haemodynamic effects.
Based on these findings, we investigated whether similar
haemodynamic changes could also be observed in hyperten-
sive patients. Directly after RDN, we showed a reduction in
the arteriolar resistance. Moreover, we observed that acute
changes in arteriolar resistance were significantly associ-
ated with the change in BP during follow-up, suggesting
this may be a marker for successful RDN.
In conclusion, RDN may be effective to lower BP. How-
ever, a large number of patients were non-responders. Our





Novel insights into the complexity of ischaemic heart
disease derived from intracoronary pressure and flow
velocity measurements
The management of ischaemic heart disease in contempo-
rary clinical practice remains governed by the extent of
focal epicardial coronary artery disease. Its diagnosis is
principally established by means of invasive coronary an-
giography, and revascularisation is preferably guided by
fractional flow reserve. Despite increasing interest in the
functional relevance of epicardial stenosis and its bene-
ficial effect on patient outcomes in the setting of stable
ischaemic heart disease, it is important to realise that is-
chaemic heart disease goes beyond the domain of the coro-
nary circulation that can be assessed by angiography and
fractional flow reserve. Both only aim to identify (func-
tionally) important epicardial coronary artery disease, and
provide limited or no information on the presence of diffuse
epicardial and microvascular disease. These conditions can
be identified by the additional assessment of coronary flow
parameters, such as coronary flow reserve and microvas-
cular resistance index. We documented that coronary flow
reserve has a dominant role over fractional flow reserve in
the prognosis of stable ischaemic heart disease after defer-
ral of revascularisation in intermediate coronary stenosis:
as long as the coronary flow reserve remains above nor-
mal thresholds, the occurrence of a pressure drop along
the coronary artery has little effect on clinical outcomes,
whereas reduced flow reserve is associated with severely
impaired clinical outcomes even in the absence of pres-
sure loss along the coronary artery, suggestive of domi-
nant microvascular disease. These data suggest that the
coronary microcirculation, which remains elusive to the in-
terventionalist in contemporary angiography and fractional
flow reserve-guided practice, plays a dominant role in the
diagnosis and risk stratification in stable ischaemic heart
disease patients. This is supported by the observation that
the identification of ischaemia-inducing coronary stenosis
by fractional flow reserve is influenced by the functional
status of the coronary microcirculation, where, for a given
stenosis, its ischaemic potential increases with increasing
microvascular resistance to coronary blood flow. These ob-
servations on the relevance of microcirculatory function and
coronary flow for the diagnosis and prognosis of stable is-
chaemic heart disease have led to the hypothesis that a pri-
mary approach towards its diagnosis should be found in
the coronary flow characteristics of the vasculature under
investigation, instead of the contemporary coronary pres-
sure-guided approach. For this purpose, and since coro-
nary flow reserve has distinct limitations due to its depen-
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concept termed coronary flow capacity. This approach is
governed by the assumption that myocardial ischaemia is
unlikely when either coronary flow reserve or maximal flow
is above normal thresholds. With increasing impairment of
both of these parameters, the likelihood of myocardial is-
chaemia and impaired clinical outcome increases. Coronary
flow capacity indeed allowed more robust risk stratification
compared with coronary flow capacity in patients with is-
chaemic heart disease. Since such a flow-based concept
is applicable to all modalities that measure flow, an ap-
proach can be anticipated that first determines the severity
of ischaemic heart disease by determining the overall flow
impairment throughout the myocardium before the epicar-
dial and microvascular contribution to flow impairment are
evaluated to determine the dominant origin of flow impair-
ment, and eligibility for coronary revascularisation.
In conclusion, this thesis dives into the complexity of is-
chaemic heart disease that derives from the complex multi-
level involvement of the coronary circulation, including not
only focal epicardial, but also diffuse and microvascular ab-
normalities that impair myocardial perfusion, and proposes
a novel flow-based approach to the diagnosis and treatment
of ischaemic heart disease patients.
T.P. van de Hoef




Ischaemic heart disease: from perfusion deficits after
microvascular injury to perfusion restoration by
arteriogenesis
The prognosis of patients suffering from ischaemic heart
disease has rapidly and greatly improved over the course
of some 35 years. Microvascular injury, however, remains
a threat to the functional recovery of ST-segment elevation
myocardial infarction (STEMI) patients. Despite successful
treatment with primary percutaneous coronary intervention
(PCI), between 40 and 50 % of STEMI patients develop mi-
crovascular injury, which is associated with negative remod-
elling and left ventricular dysfunction, leading to decreased
long-term survival, increased morbidity and reduced quality
of life.
In this thesis, intracoronary physiology indices were
shown to be valuable in predicting the occurrence of mi-
crovascular injury and microvascular perfusion deficits after
angiographically successful primary PCI. In a prospective
clinical study of 60 patients presenting with STEMI, hy-
peraemic microvascular resistance, measured immediately
following angiographically successful PCI, was shown to
predict microvascular injury as assessed by cardiac mag-
netic resonance (CMR) and reduced myocardial blood flow
as quantified by positron emission tomography. Further-
more, a cut-off for hyperaemic microvascular resistance
(2.5 mmHg/cm · s) was established for predicting exten-
sive microvascular injury. Moreover, in STEMI patients
a disbalance was shown between “a disintegrin-like and
metalloprotease with thrombospondin type motif no. 13”
(ADAMTS13) and von Willebrand factor towards a hyper-
coagulable sate. Recombinant ADAMTS13 was tested as
a therapeutic strategy in myocardial ischaemia-reperfusion
injury in a preclinical porcine model. In a translational
approach, combining data from our clinical study with
preclinical data, we investigated the histopathological cor-
relate of CMR findings of microvascular injury. Areas
of CMR-defined microvascular obstruction after acute
myocardial infarction were shown to actually represent
microvascular destruction and intramyocardial haemor-
rhage.
In chronic myocardial ischaemia, collateral artery forma-
tion or arteriogenesis is potentially a tissue and lifesaving
mechanism. Therapeutic strategies aiming to enhance arte-
riogenesis could be a valuable addition to the therapeutic
arsenal of cardiologists treating patients with advanced is-
chaemic cardiomyopathy. Due to the important side effects
of strategies aimed at accelerating arteriogenesis investi-
gated hitherto, such as acceleration of atherosclerosis, to
date no such strategy has found its way to clinical prac-
tice. The second part of this thesis discusses the coro-
nary collateral circulation in experimental models and hu-
mans as well as clinical parameters associated with col-
lateral development in patients. Finally, an elaborate ex-
perimental approach to stimulate arteriogenesis was ex-
plored. We demonstrate that blocking the interferon al-
pha and beta receptor using monoclonal antibodies acceler-
ates arteriogenesis in mice without influencing atheroscle-
rosis.
In conclusion, this thesis provides new and important
insights regarding vascular damage and healing in cardiac
ischaemic syndromes which will ultimately support the de-
sign of therapeutic strategies to combat microvascular in-
jury and to stimulate collateral artery growth.
P.F.A. Teunissen
Interventional Cardiology VU University Medical Center,
Amsterdam, the Netherlands
Email: pf.teunissen@vumc.nl
Dr. van de Hoef won the first prize, dr. Verloop the second
prize, and dr. Teunissen the third prize.
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